Sintilimab in FH-deficient Renal Cell Carcinoma

NCT04146831 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma
FH-deficient
Sintilimab

Interventions

DRUG: Sintilimab

Sponsor

West China Hospital